CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 12,248 enrolled
Drug / intervention
Sugammadex 100 MG/ML [Bridion]drug
Likely dose
Sugammadex 100 MG/ML [Bridion]from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04263363
NCT04263363Phase 4Completed
CompareCT.gov

A Prospective Digital Quality Improvement Project to Apply Best Clinical Practices to Patients at High Risk of Respiratory Complications

University of California, Los Angeles·interventional·Posted Feb 10, 2020·Updated Jul 29, 2025

In Brief

A Phase 4 clinical trial evaluating Sugammadex 100 MG/ML [Bridion] for Respiratory Complication and Obstructive Sleep Apnea. Completed, enrolled 12,248 participants across 1 site.

Detailed Summary

The purpose of this study is to: 1. Perform a retrospective analysis on data contained in the UCLA Perioperative Data Warehouse on the incidence of respiratory dysfunction in the post-operative care unit (PACU) before and after the introduction of sugammadex into clinical practice. 2. Develop and implement a clinical best practice pathway designed to prevent postoperative respiratory complications in higher risk patients (such as those with OSA or preexisting respiratory disease) using education and clinical decision support in patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRespiratory Complication, Obstructive Sleep Apnea
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC

Timeline

Phase 4CompletedFinished
2020202120222023202420252026
First PostedFeb 10, 2020
Enrollment StartFeb 18, 2022
Primary CompletionMay 7, 2024
Study CompletionMay 7, 2025
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 6.4 years ago

Interventions

Sugammadex 100 MG/ML [Bridion]drug

Sugammadex administered to patients within the clinical best practice pathway.